Targeted Pathways in Psoriasis and Psoriatic Arthritis - Implications for Improved Patient OutcomesPremiere Date: Wednesday, November 7, 2018
This activity offers CE credit for:%>
- Physicians (CME)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Thursday, November 7, 2019
Note: Credit Is No Longer Available
|Allan Gibofsky, MD, JD, MACR, FACP, FCLM (Moderator)
Professor of Medicine, Healthcare Policy and Research
Weill Medical College of Cornell University
Hospital for Special Surgery
New York, NY
|Joel M. Gelfand, MD, MSCE
Professor of Dermatology
Professor of Epidemiology
Vice Chair of Clinical Research and Medical Director, Dermatology Clinical Studies Unit
Director, Psoriasis and Phototherapy Treatment Center
University of Pennsylvania Perelman School of Medicine
|Jennifer G. Kwan-Morley, MD
Psoriatic arthritis (PsA) is a serious and potentially disabling condition that effects about 30% of patients with psoriasis. Increased understanding of the pathogenesis of PsA has highlighted the critical importance of the action of several inflammatory cytokines, including tumor necrosis factor (TNF)-α, interleukin (IL)-23, and IL-17 in the development of the disease. However, clinicians often lack a thorough understanding of these molecular targets and drugs designed to target these pathways.
Since 2008, several agents have been FDA-approved for the treatment of PsA, and there are several agents currently under investigation. As clinicians treat patients with PsA, continuing education regarding molecular targets of emerging agents to make informed treatment decisions is needed.
Join CME Outfitters and our expert faculty in this CME Snack for a discussion about PsA treatment strategies and best implementation practices for current and emerging biologic treatment options with a focus on molecular targets.
At the end of this CE activity, participants should be able to:
- Identify the molecular targets of currently available and emerging treatments for the management of psoriatic arthritis.
Supported by educational grants form Celgene Corporation; Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC.; and Novartis Pharmaceuticals Corporation.
Rheumatologists, dermatologists, physicians, physician assistants, nurse practitioners, nurses, and pharmacists who treat patients with psoriatic arthritis.
CME Credit (Physicians):
USF Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
USF Health designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
It is the policy of USF Health and CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Gibofsky reports that he is on the Speakers Bureau for AbbVie Inc.; Celgene Corporation; Merck & Co., Inc.; and Pfizer, Inc. He is a consultant for AbbVie Inc.; Celgene Corporation; Merck & Co., Inc; Pfizer Inc.; Samumed, LLC; and Sandoz. He is a stock shareholder of AbbVie Inc.; Bristol-Myers Squibb Company; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Pfizer Inc..
Dr. Gelfand reports that he receives research grants (to the Trustees of the University of Pennsylvania) from AbbVie Inc.; Celgene Corporation; Janssen Biologics, Inc.; Novartis Corporation, Pfizer Inc.; Ortho Dermatologics, Inc.; and Sanofi. He is a consultant for Bristol-Myers Squibb Company; Boehringer Ingelheim; GlaxoSmithKline; Janssen Biologics, Inc.; Novartis Corporation; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi; and UCB Data and Safety Monitoring Board (DSMB).
Dr. Kwan-Morley has no disclosures to report.
Kate Nelson, PHD (planning committee) has no disclosures to report.
Sharon Tordoff(planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Disclosures were obtained from the USF Health staff: No disclosures to report.
CME Outfitters, LLC, USF Health, and the faculty do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).